Advances in medicine come from new ideas developed through clinical trials and research. At Renown Health, we conduct hundreds of clinical trials (also called research trials or research studies) in our ongoing effort to discover and deliver more effective treatments.

Our goal is to translate discoveries made in the laboratory to the patients who will benefit from them, and to do it as quickly as possible.

Select a category from the list below, and contact us for a more thorough explanation of each study.


 

Cardiology

ARTEMIS

Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year.

AUGUSTUS

An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention.

CardioMEMS

The CardioMEMS HF System consists of a wireless, battery-less pressure sensor implanted into the pulmonary artery and an external electronics that powers and communicates with the sensor and transmits pulmonary artery pressure waveforms and measurements to a secure website for Investigator review and patient management.

CIRT Study

To test the inflammatory hypothesis of atherothrombosis. Specifically, CIRT will evaluate whether LDM will reduce rates of myocardial infarction, stroke, or cardiovascular death among patients with a recent history of coronary artery disease and either type 2 diabetes or metabolic syndrome, conditions associated with an enhanced pro-inflammatory response.

DECLARE Study

This study is being carried out to see if dapagliflozin when added to a patient’s current anti-diabetes therapy is effective in reducing cardiovascular events such as myocardial infarction (MI) (heart attack), ischemic stroke, and cardiovascular (CV) related death, compared with placebo (inactive study medication).

Galactic

To assess the treatment of omecamtiv mecarbil (OM) compared with placebo when added to the normal standard of care in Heart Failure patients. To analyze the reduction of Heart Failure hospitalization and improved symptoms in subjects with chronic Heart Failure with Reserved Ejection Fraction (HFrEF). Treatment goals are to improve symptoms, prolong survival and reduce hospital readmissions.

GLORIA-AF Study

To investigate the differences between patients that may influence the choice of anticoagulation medication that is selected for the prevention of stroke in AF patients, and to collect information on important health related events and anticoagulation treatments related to AF in a real-world setting and potential side effects of anticoagulant treatment (patients being treated in a doctor's office as opposed to research data gathered during a controlled research study).

MRI DI

Asses the image quality, clinical impact, and diagnostic utility of MRI in patients undergoing clinically indicated, non-thoracic MRI scans who are implanted with a St. Jude Medical pacemaker, ICD, or CRT device. The study population includes males and females implanted with a St. Jude Medical pacemaker, ICD, or CRT device system and are who clinically indicated for a non-thoracic MRI scan.

PARADISE-MI

The purpose of this study is to evaluate the efficacy and safety of LCZ696 compared to ramipril, in reducing the occurrence of cardiovascular (CV) death, heart failure (HF) hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of left ventricular (LV) systolic dysfunction and/or pulmonary congestion, without a known prior history of chronic HF.

Perspective

The purpose of this study is to evaluate the effect of Entresto compared to valsartan on cognitive function in patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The patients will be evaluated for three years assessing the memory, executive function, and attention.

PIONEER

The purpose of this study is to assess the effect of in-hospital initiation of acubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).

RADIANCE

The objective of the RADIANCE-HTN study is to demonstrate the efficacy and verify the safety of the Paradise System in two distinct populations of hypertensive subjects. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication or despite the presence of a stabilized, single pill, triple, fixed dose antihypertensive medication regimen.

SMARTADHERE

To evaluate the effectiveness of an intervention with a mobile adherence platform, compared to physician- or nurse-guided standard of care, to improve medication adherence to rivaroxaban in subjects who have recently initiated treatment with rivaroxaban for stroke prevention in atrial fibrillation based on an assessment of the PDC of rivaroxaban treatment.

SVEAT

Acute chest pain is one of the most common presenting symptoms in emergency department (ED). Accurately identifying low risk patients who may be eligible for early discharge has significant impact on patient care and resource utilization. SVEAT is a scoring system that incorporates appropriate and precise clinical information to improve the capability to accurately identify low risk acute chest pain patients presenting to ED.

 

Neurology

ARAMIS Study

  1. Examine the prevalence of preadmission NOA use in patients who present with AIS or ICH;
  2. Describe and characterize diagnostic tests being used to assess level of anticoagulation when a patient presents with AIS or ICH on one of the NOA;
  3. Examine the utilization and safety profile of thrombolytic therapy in AIS patients on NOA as compared with those on warfarin;
  4. Document current practice patterns for the care of oral anticoagulant-related ICH and determine how treatment and clinical outcomes vary by NOA and warfarin therapy

PROMISE

The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.

RESPECT ESUS

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).

 

Oncology

As the largest healthcare system in northern Nevada and eastern California, and in partnership with the National Cancer Institute and the Nevada Cancer Research Foundation, we have access to dozens of open clinical trials.

We provide education and guidance to help patients make decisions about their care and treatment. Our specially trained research nurses will help you understand the process and explain what to expect with each visit. We are committed to bringing the highest quality of cancer care to you and your loved ones.

 

Pediatrics

Sentinel Study

Purpose of this study is to evaluate clinical, humanistic and health economic burden of Respiratory Syncytial Virus (RSV) in infants born 29 to 35 Weeks Gestational Age (wGA) hospitalized for RSV at up to 12 months of age.

Regeneron

Part B of the study is randomized, double-blind, and placebo-controlled, designed to evaluate the efficacy, safety, serum concentration and immunogenicity of IM administration of REGN2222 in preterm infants for whom palivizumab is not recommended.

 

Pulmonology

No trials found.